Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Interest Expenses (2017 - 2025)

Purple Biotech has reported Interest Expenses over the past 6 years, most recently at -$41000.0 for Q4 2022.

  • Quarterly Interest Expenses fell 159.42% to -$41000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $67000.0 through Dec 2022, down 68.4% year-over-year, with the annual reading at $982000.0 for FY2025, 103.31% up from the prior year.
  • Interest Expenses was -$41000.0 for Q4 2022 at Purple Biotech, down from $16000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $196000.0 in Q4 2018 and troughed at -$41000.0 in Q4 2022.
  • The 5-year median for Interest Expenses is $48500.0 (2020), against an average of $62833.3.
  • Year-over-year, Interest Expenses skyrocketed 931.58% in 2018 and then tumbled 159.42% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $196000.0 in 2018, then crashed by 62.76% to $73000.0 in 2019, then tumbled by 36.99% to $46000.0 in 2020, then soared by 50.0% to $69000.0 in 2021, then tumbled by 159.42% to -$41000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Interest Expenses are -$41000.0 (Q4 2022), $16000.0 (Q3 2022), and $51000.0 (Q2 2022).